Norepinephrine

Evidence Level: L4

Predicted Indications: 3

Norepinephrine

Pharmacist Assessment Report

Norepinephrine: Obstructive lung disease

One-Sentence Summary

Norepinephrine is an adrenergic vasopressor, originally listed for conditions such as asthma, bronchitis, emphysema, bronchiectasis and hypotensive disorders. The TxGNN model predicts it may be effective for obstructive lung disease, but the supporting evidence is thin: 1 clinical trial (indirectly related) and 19 publications, mostly mechanistic reviews.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Obstructive lung disease
TxGNN Prediction Score	0.9984
Evidence Level	L4
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Norepinephrine is an adrenergic agonist with alpha-1, alpha-2 and beta-1 activity, and weak beta-2 activity. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description is based on general pharmacological knowledge.

Asthma, bronchitis, emphysema and bronchiectasis already appear among its original indications. Obstructive lung disease (such as COPD and asthma) overlaps heavily with these conditions, which is why the model links them. The literature supports a role for adrenergic and neuroimmune signalling in airway disease, but this is mechanistic and review-level evidence.

There are important limits. Norepinephrine’s beta-2 bronchodilator activity is weak, and no modern evidence shows it improves outcomes in obstructive lung disease. Its vasoconstrictor, tachycardic and arrhythmic effects are a concern in COPD patients who also have heart disease or hypoxaemia.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02966665	Phase 1	Recruiting	420	Vascular function, exercise and skeletal muscle feedback in hypertension. Not designed to test norepinephrine in obstructive lung disease; the link is indirect (relevance grade C).

Literature Evidence

No randomised trials were found. The most relevant items are reviews and physiology studies.

PMID	Year	Type	Journal	Key Findings
29696025	2018	Review	Front Immunol	Adrenergic signalling at the interface of allergic asthma and viral infections
41601146	2026	Review	Ann Med	Neuroimmune circuits in respiratory disease and potential therapeutic targets
21271508	2011	Review	Pneumologie	Airway innervation in asthma and COPD, including the role of norepinephrine in sympathetic nerves
2003685	1991	Review	Am Rev Respir Dis	Neural control of airway blood vessels and oedema; sympathetic norepinephrine acts as a constrictor
10951892	2000	Review	Allergy Asthma Proc	Stress, immune regulation and asthma; lymphocytes carry norepinephrine receptors
28539203	2018	Review	Allergol Int	Neuroendocrine activity and stress-induced worsening of allergic asthma
29030339	2018	Physiology study	Am J Physiol Heart Circ Physiol	Muscle alpha-adrenergic responsiveness during exercise in COPD patients
35870527	2022	Panel study	Environ Pollut	Stress hormones and air pollution exposure in people with and without COPD
11099681	2000	Clinical study	Am J Med	Mechanisms of hypertension in COPD with acute respiratory failure, including norepinephrine levels
3332227	1987	Review	Crit Care Clin	Catecholamines in critical care

India Market Information

Twenty single-ingredient injectable licences are valid in India, with none cancelled. The approved indication text is blank for all of them. Five examples:

Authorization Number	Product Name	Dosage Form	Approved Indication
152051	Norbit Injection	Vial of 2 ml injection	Not stated
153832	N-Adrin 4mg Injection	Vial of 2 ml injection	Not stated
157407	Nordyx Injection	Ampoule of 2 ml injection	Not stated
1359	Adrenor 4mg Injection	Vial of 2 ml injection	Not stated
150671	Norad 4mg Injection	Vial of 4 ml injection	Not stated

All products are injections; no inhaled or oral forms are registered, which matters for a respiratory indication.

Safety Considerations

Contraindications (from the knowledge graph, not label text): hypertensive disorder, hypertension, thrombotic disease.
Drug Interactions: 70 interactions were identified, all of those listed rated Moderate. They are mainly with antidiabetic drugs (e.g., metformin, pioglitazone, sitagliptin, semaglutide, insulins, SGLT2 inhibitors) and with the anorectics phentermine and diethylpropion.

Package-insert warnings and contraindications were not available; please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The high TxGNN score (0.9984) is not backed by direct clinical evidence: the only trial is an indirect Phase 1 hypertension study, and the literature is mechanistic. Norepinephrine’s cardiovascular effects add risk in COPD patients, and the registered products are injections only.

To proceed, the following is needed:

Package-insert warnings and contraindications (blocking for safety screening)
Mechanism of action data
Controlled clinical data in obstructive lung disease, or a clear rationale for an appropriate route and setting
A cardiovascular risk assessment for patients with COPD and comorbid heart disease or hypoxaemia

Other predictions, not recommended for further work at this stage:

Respiratory malformation (score 0.9984, L5): no clinical trials, and the literature is physiological or safety-related. A vasopressor has no clear therapeutic role.
Rienhoff syndrome (score 0.9983, L5): no trials or literature; this is a computational hypothesis only.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.